| Name | Title | Contact Details |
|---|---|---|
Katie Otto |
Director, Legal Services | Profile |
Soo-Yeun Lim |
Vice President, Corporate Legal | Profile |
Brian Adams |
General Counsel | Profile |
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.
Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.
Metabolix, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Diana Plants Sciences (Diana Group) is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VBI Vaccines Inc.is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.